The findings presented here demonstrate that i.t application of LA, a nominated TRPC6 blocker, exerts strong analgesic actions in SNI-induced neuropathic pain, which may be ascribed to the TRPC6-pp38-dependent suppression of microglia activation and the anti-inflammatory roles in inhibiting the increased level of proinflammatory cytokines in the spinal cord. The gene discussed is TRPC6; the disease is neuropathic pain.